By Megan McKnelly* and S. Christian Platt

On December 3, 2020, the Patent Trial and Appeal Board (“PTAB”) released data regarding the usage and success rates of its Motion to Amend (“MTA”) Pilot Program (“Pilot”). All PTAB cases instituted on or after March 15, 2019, are eligible for the Pilot, which provides two new options for MTA filers. The options include: (1) requesting preliminary guidance from the PTAB on a MTA and/or (2) filing a revised MTA after preliminary guidance or the petitioner’s opposition to the original MTA.

The PTAB reported that between June 1, 2019, and September 30, 2020, it received 102 Pilot-eligible MTAs. Of those filed, 76% of MTAs opted to receive preliminary guidance and 79% opted to file revised MTAs under the Pilot. These opt-in rates differ from the previous rates reported by the PTAB for MTAs filed between June 1, 2019, and March 31, 2020, where 83% of MTAs opted to receive preliminary guidance and 58% opted to file revised MTAs.

The PTAB also announced the initial success rates of MTA filers opting into the Pilot. From April 1, 2020, to September 30, 2020, the PTAB issued 31 Final Written Decisions for Pilot-eligible MTAs. Of those 31 MTAs, nine did not elect one of the Pilot options; those MTAs were 11% successful in obtaining at least one proposed substitute claim. On the other hand, the 22 MTAs that did elect one or both Pilot options were 36% successful in the same regard. The success rate of MTAs opting into the Pilot is considerably higher than the success rate of pre-Pilot MTAs, of which only about 14% of MTAs were granted at least one proposed substitute claim. As expressed in the PTAB’s announcement, this “data indicates that the pilot program is working as intended.”

*Megan recently joined the New Lawyer Group in Jones Day’s San Diego Office

The following two tabs change content below.

S. Christian Platt

Christian Platt is an experienced patent trial lawyer who handles complicated intellectual property disputes in the courts and the patent office, including patent infringement, patent validity, trade secret, and licensing disputes. He has tried multiple bench and jury trials. Christian has represented some of the world's largest companies in their most complex patent disputes involving, in many instances, more than a billion dollars in potential damages. He handles a variety of technologies, including biotechnology, pharmaceuticals, telecommunications, video games, computer hardware, software, networking technologies, and medical devices.